ES2813407T3 - Métodos para generar células madre mesenquimales que secretan factores neurotróficos - Google Patents

Métodos para generar células madre mesenquimales que secretan factores neurotróficos Download PDF

Info

Publication number
ES2813407T3
ES2813407T3 ES13767124T ES13767124T ES2813407T3 ES 2813407 T3 ES2813407 T3 ES 2813407T3 ES 13767124 T ES13767124 T ES 13767124T ES 13767124 T ES13767124 T ES 13767124T ES 2813407 T3 ES2813407 T3 ES 2813407T3
Authority
ES
Spain
Prior art keywords
growth factor
mesenchymal stem
stem cells
secrete
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13767124T
Other languages
English (en)
Inventor
Yael Gothelf
Yosef Levy
Alex Burshtein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brainstorm Cell Therapeutics Ltd
Original Assignee
Brainstorm Cell Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brainstorm Cell Therapeutics Ltd filed Critical Brainstorm Cell Therapeutics Ltd
Application granted granted Critical
Publication of ES2813407T3 publication Critical patent/ES2813407T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/195—Heregulin, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pathology (AREA)

Abstract

Un método para generar células que secretan el factor neurotrófico derivado del cerebro (FNDC), factor neurotrófico derivado de la glía (FNDG), factor de crecimiento de hepatocitos (FCH) y factor de crecimiento endotelial vascular (VEGF), en donde dichas células no secretan factor de crecimiento nervioso (NGF) que comprende incubar una población de células madre mesenquimales (MSC) humanas, indiferenciadas, obtenidas de la médula ósea en un medio de diferenciación que comprende el factor de crecimiento básico de fibroblastos (bFGF), factor de crecimiento derivado de plaquetas (PDGF), heregulina y AMPc, en donde dicha incubación se efectúa en una sola etapa, en donde dicho medio de diferenciación carece de IBMX, generando así las células.
ES13767124T 2012-08-06 2013-08-04 Métodos para generar células madre mesenquimales que secretan factores neurotróficos Active ES2813407T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261679822P 2012-08-06 2012-08-06
PCT/IL2013/050660 WO2014024183A1 (en) 2012-08-06 2013-08-04 Methods of generating mesenchymal stem cells which secrete neurotrophic factors

Publications (1)

Publication Number Publication Date
ES2813407T3 true ES2813407T3 (es) 2021-03-23

Family

ID=49253370

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13767124T Active ES2813407T3 (es) 2012-08-06 2013-08-04 Métodos para generar células madre mesenquimales que secretan factores neurotróficos

Country Status (10)

Country Link
US (3) US10046010B2 (es)
EP (1) EP2880151B1 (es)
JP (2) JP6362596B2 (es)
BR (1) BR112015001435B1 (es)
CA (1) CA2877223C (es)
DK (1) DK2880151T3 (es)
ES (1) ES2813407T3 (es)
HK (1) HK1209453A1 (es)
IL (1) IL261441B (es)
WO (1) WO2014024183A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2880151B1 (en) 2012-08-06 2020-06-03 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
TWI648273B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
CA2937305C (en) 2014-02-11 2020-12-15 Brainstorm Cell Therapeutics Ltd. Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells
US20170247660A1 (en) * 2014-09-18 2017-08-31 National Health Research Institutes Progenitor cells, method for preparation thereof and uses thereof
EP3819372A3 (en) 2015-04-24 2021-10-06 University of Copenhagen Isolation of bona fide pancreatic progenitor cells
CN105169486B (zh) * 2015-10-11 2018-04-03 温州医科大学 一种结合去细胞神经应用的神经修复材料
GB2605113A (en) * 2016-05-09 2022-09-21 Sistemic Scotland Ltd Functional prediction
EP3455367A1 (en) 2016-05-09 2019-03-20 Sistemic Scotland Ltd Functional prediction of cellular functions by means of microrna expression profiling in mesenchymal stem cells
GB2550136A (en) * 2016-05-09 2017-11-15 Sistemic Scotland Ltd Functional prediction
KR20220126789A (ko) 2016-07-18 2022-09-16 브레인스톰 셀 세라퓨틱스 리미티드 근위축성 측색 경화증 (als)의 치료 방법
WO2018046774A1 (en) * 2016-09-12 2018-03-15 Genethon Acid-alpha glucosidase variants and uses thereof
US20200246386A1 (en) * 2017-04-24 2020-08-06 Pluristem Ltd. Methods and compositions for treating neurological disorders
US20190054144A1 (en) * 2017-08-15 2019-02-21 Meridigen Biotech Co., Ltd. Pharmaceutical composition for treating ischemic stroke and method thereof
US11286462B2 (en) 2017-09-14 2022-03-29 University Of Kansas Materials and methods for generating therapeutic mesenchymal stem cells
WO2019051536A1 (en) * 2017-09-15 2019-03-21 Cynata Therapeutics Limited METHOD OF TREATING ALLERGIC RESPIRATORY TRACT DISEASE (DAA) / ASTHMA
CA2983845C (en) 2017-10-26 2024-01-30 University Of Copenhagen Generation of glucose-responsive beta cells
EP3773620A1 (en) * 2018-04-10 2021-02-17 Brainstorm Cell Therapeutics Ltd. Cell-type specific exosomes and use thereof
US20200000886A1 (en) * 2018-06-29 2020-01-02 University Of Washington Engineering the rrm2 subunit of ribonucleotide reductase to resist degradation
CN111484978A (zh) * 2019-01-28 2020-08-04 深圳市第二人民医院 miR-140-5p过表达修饰的人脐带间充质干细胞、其治疗制剂、制备方法和应用
KR20210138655A (ko) 2019-03-14 2021-11-19 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 근위축성 측삭 경화증의 치료용 의약 조성물
KR102323056B1 (ko) * 2019-05-02 2021-11-09 에스씨엠생명과학 주식회사 hPL 함유 배지에서 배양된 중간엽 줄기세포의 배양액을 포함하는 화장료 조성물
JPWO2020250913A1 (es) * 2019-06-11 2020-12-17
JP2023517230A (ja) * 2020-03-11 2023-04-24 リモーター セラピューティクス インコーポレイテッド 中枢神経系全体にわたってタンパク質を散在させるための方法および材料
WO2022091086A1 (en) * 2020-10-26 2022-05-05 Hadasit Medical Research Services And Development Ltd. Mesenchymal stem cells and their culture
EP4316498A1 (en) 2021-03-30 2024-02-07 Kaneka Corporation Trypsin inhibition method, and method for producing cell preparation in which same is used
CN113367123B (zh) * 2021-06-07 2022-05-13 南京三生生物技术股份有限公司 一种细胞冻存方法
CN113789333B (zh) * 2021-09-07 2023-07-14 中国人民解放军军事科学院军事医学研究院 Chi3l1在调控hUC-MSCs抑制Th17分化介导的免疫调节作用上的应用
WO2023219655A1 (en) * 2022-05-13 2023-11-16 University Of Utah Research Foundation Gja1-20k to limited cardiac arrhythmias
CN116410921B (zh) * 2023-02-09 2024-01-23 北京益华生物科技有限公司 一种人源脐带间充质干细胞诱导培养基、诱导方法及应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
DE69534151T2 (de) 1994-02-22 2006-01-12 Nippon Telegraph And Telephone Corp. Gefriergetrocknete Blutzellen, Stammzellen und Plättchen und Verfahren zu deren Herstellung
US5955257A (en) 1997-10-21 1999-09-21 Regents Of The University Of Minnesota Infusible grade short-term cell storage medium for mononuclear cells
JP3948971B2 (ja) * 2001-08-30 2007-07-25 サンバイオ，インコーポレイティド Ｎｏｔｃｈ遺伝子の導入を用いて骨髄間質細胞を神経細胞及び骨格筋細胞に分化・誘導する方法
CA2475288C (en) 2002-02-06 2014-09-02 Sanbio, Inc. Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene
US20030215942A1 (en) 2002-02-14 2003-11-20 Stemcyte, Inc. Undesignated allogeneic stem cell bank
IL152905A0 (en) 2002-11-17 2003-06-24 Univ Ramot Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease
US20050265983A1 (en) 2002-11-17 2005-12-01 Eldad Melamed Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
CN101243178A (zh) * 2005-06-16 2008-08-13 特拉维夫大学拉莫特有限公司 用于治疗cns疾病的分离细胞和包含这种细胞的细胞群
US20100021434A1 (en) 2005-12-08 2010-01-28 Ramot At Tel Aviv University Ltd. Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases
EP3514229A1 (en) 2008-05-28 2019-07-24 Ramot at Tel-Aviv University Ltd. Mesenchymal stem cells for the treatment of cns diseases
US20100184033A1 (en) 2008-07-16 2010-07-22 West Michael D Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
EP2501802A4 (en) 2009-11-17 2013-08-21 Advanced Cell Tech Inc METHOD FOR PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS FROM HUMAN RPE CELLS
DE102011121982B3 (de) 2011-12-22 2013-04-18 Dietmar Hopp Stiftung GmbH Mesenchymale Stammzellen aus Fettgewebe (ADSC) zur Rekonstruktion von Haut und Weichteilgewebe
EP2880151B1 (en) 2012-08-06 2020-06-03 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
CA2937305C (en) 2014-02-11 2020-12-15 Brainstorm Cell Therapeutics Ltd. Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells

Also Published As

Publication number Publication date
HK1209453A1 (en) 2016-04-01
US10046010B2 (en) 2018-08-14
EP2880151B1 (en) 2020-06-03
BR112015001435B1 (pt) 2022-01-18
US20180296607A1 (en) 2018-10-18
JP6362596B2 (ja) 2018-07-25
BR112015001435A2 (pt) 2018-07-31
JP2015531594A (ja) 2015-11-05
EP2880151A1 (en) 2015-06-10
JP2018138044A (ja) 2018-09-06
US20210338739A1 (en) 2021-11-04
US20150209389A1 (en) 2015-07-30
IL261441B (en) 2019-10-31
JP6753887B2 (ja) 2020-09-09
IL261441A (en) 2018-10-31
WO2014024183A1 (en) 2014-02-13
DK2880151T3 (da) 2020-08-17
CA2877223C (en) 2019-08-27
CA2877223A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
ES2813407T3 (es) Métodos para generar células madre mesenquimales que secretan factores neurotróficos
CY1119924T1 (el) Μεθοδος για παρασκευη ενος βασικου μεσου καλλιεργειας για μεσεγχυματικα βλαστοκυτταρα, βασικο μεσο καλλιεργειας για μεσεγχυματικα βλαστοκυτταρα, και κυτταρικος θεραπευτικος παραγοντας καλλιεργημενος και διαφοροποιημενος με χρηση αυτου
WO2015121859A8 (en) Method of qualifying cells
BR112016026626A2 (pt) Uso de moléculas pequenas para melhorar a expressão de mafa em células pancreáticas endócrinas
RU2012121842A (ru) Способ получения мезенхимальных стволовых клеток из плюрипотентных стволовых клеток человека и мезенхимальные стволовые клетки, полученные этим способом
MX2017010377A (es) Andamios e implantes de tejidos suaves biológicamente funcionales.
CA2863795A1 (en) Culturing of mesenchymal stem cells
MY183058A (en) Production method for retinal tissue
NZ715302A (en) Renal progenitor cells
PH12015501477A1 (en) Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
BR112021015887A8 (pt) Método para criopreservação de célula-tronco, população de células-tronco, composição de criopreservação, uso de nac, e kit de criopreservação
AR082820A1 (es) Diferenciacion de celulas madre embrionarias humanas
NZ599407A (en) Methods of preparing mesenchymal stem cells, compositions and kit thereof
PH12017501153A1 (en) Suspension culturing of pluripotent stem cells
SG11201505965TA (en) Culture method for stable undifferentiated proliferation of pluripotent stem cells
EP3263697A4 (en) Culture medium for culturing mesenchymal stem cell, method for culturing mesenchymal stem cell, and mesenchymal stem cell
SG10201903910RA (en) Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same
ATE525460T1 (de) Verfahren zur kultivierung und vermehrung hämatopoetischer stammzellen und vorläuferzellen unter verwendung menschlicher endometriumzellen
MX2018010828A (es) Medio para formar colonias y uso de este.
CL2019000318A1 (es) Método para producir un l-aminoácido tal como l-lisina.
AU2017255099A1 (en) Purification method for pancreatic precursor cells derived from pluripotent stem cells and amplification method therefor
MX2015012168A (es) Expansión de celulas madre adultas in vitro.
WO2014027176A3 (en) Stem cell culture method
EP3848455A4 (en) Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby
WO2014113704A3 (en) Enhanced differentiation of mesenchymal stem cells